Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection

Nated, 0 to 13 days, 14 to 27 days, 1 to 2 months, 3 to 4 months, 5 to 6 months, 7 to 8 months, or ≥9 months).Among the patients who had received two doses of vaccine, waning of effectiveness against hospitalization was evident as early as 3 to 4 months after vaccination during both periods when the omicron sublineages were dominant.The vaccine effectiveness was 56.3% (95% confidence interval [CI], 51.6 to 60.5) during the BA.1-BA.2wave and 47.4% (95% CI, 19.9 to 65.5) during the BA.4-BA.5 wave (Table 1).Although boosting with a third dose maintained vaccine effectiveness against severe disease caused by all four sublineages at 1 to 2 months, the vaccine effectiveness had decreased by 3 to 4 months to an…

• BA
  Bill and Melinda Gates Foundation
• H
  Hjärt-Lungfonden
• KO
  Knut och Alice Wallenbergs Stiftelse
• V
  Vetenskapsrådet
• CF
  Center for Innovative Medicine